Neoadjuvant pyrotinib plus ARX788 for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies whether combining pyrotinib with ARX788 given before surgery can work better and be safe in people with HER2-positive breast cancer. It’s designed for tumors that did not respond well enough to earlier trastuzumab and pertuzumab treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 18 to 75
- You have invasive HER2-positive breast cancer that is stage II–III
- You already had trastuzumab and pertuzumab before surgery, and your tumor response was not good enough (called SD/PD or not operable or not eligible for breast-conserving surgery)
- Your heart and basic blood counts are strong enough (including a heart pumping test showing ejection fraction at least 50%)
- You can have a needle biopsy and you’re willing to follow the study schedule and visits
- You are not taking other anti-cancer treatments at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a new combination of two targeted drugs (SHR-A1811 and pyrotinib) for HER2-positive breast cancer that has spread or is locally advanced and has grown despite previous treatments. The goal is to see if this combination can shrink tumors and slow the cancer's growth.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.